C—Side by side

Compare

Up to four peptides. Opinion rows are labeled. Copy the URL to share.

Highlight differences

Field	Cagrilintide	Semaglutide
Type	Investigational	FDA Approved
Regulatory status	Investigational; not FDA-approved	FDA-approved (Ozempic, Rybelsus, Wegovy)
Compounding status	Trial use only	Approved product (not applicable)
FDA-approved indications	None	Product-specific: type 2 diabetes; chronic weight management in eligible adults and adolescents; cardiovascular risk reduction in eligible adults; kidney/CV risk reduction in adults with type 2 diabetes and CKD; noncirrhotic MASH with F2-F3 fibrosis in adults (accelerated approval).
Categories	Metabolic / GLP-1	Metabolic / GLP-1
Claimed uses	— Claimed to increase fullness through an amylin signal — Claimed to add weight loss when combined with semaglutide	— Reported to lower blood glucose — Reported to reduce body weight in large trials
Mechanism	Long-acting amylin analogue that activates amylin receptors involved in satiety and reduced food intake.	GLP-1 receptor agonist that increases glucose-dependent insulin secretion, reduces glucagon and food intake, and delays gastric emptying.
Evidence level	Human trials ongoing	Human RCTs (approved use)
Evidence / Hype (opinion)	Evidence Hype	Evidence Hype
Momentum (opinion)	Rising	Steady
Routes	—	Injection, Oral
WADA	Prohibited	Not prohibited
Where it stands (opinion)	Randomized phase 2 evidence supports weight-loss activity, with phase 3 development underway. WADA S0 applies to unapproved pharmacological substances such as cagrilintide.	An established prescription therapy with multiple outcome-based indications. Compounded versions are not FDA-approved or interchangeable with approved products.
Last reviewed	2026-10-30	2026-10-30
News (30d)	0	1